In a significant move to bridge the gap between clinical healthcare and daily nutritional needs, Unite Us and Instacart announced a strategic partnership on Tuesday aimed at streamlining "food-as-medicine" programs. This collaboration integrates Unite Us’ advanced care coordination technology with Instacart’s massive delivery infrastructure and "Instacart Health" suite of tools. The primary objective is to […]
Tiny Health, an Austin-based health technology company specializing in microbiome sequencing and personalized health insights, has announced the successful closure of a $33 million Series B funding round. This latest investment, led by B Capital, brings the company’s total capital raised to $46 million and marks a significant milestone in the effort to transition microbiome […]
The trajectory of AliveCor, a pioneer in the digital health space, serves as a quintessential case study for the broader evolution of the medical technology industry. Founded in 2010 by Dr. David Albert, the San Francisco-based company initially garnered headlines for its novel iPhone-attached sensor, which allowed licensed medical professionals to capture electrocardiograms (EKGs) in […]
The U.S. Food and Drug Administration (FDA) has granted approval to Atebrioz (zilurgisertib), a once-daily oral medication developed for the treatment of fibrodysplasia ossificans progressiva (FOP), a devastating and ultra-rare genetic disorder. The regulatory milestone, announced following the close of market operations on Friday, positions Mirum Pharmaceuticals to commercialize the drug for both adult and […]
San Diego-based biotechnology firm ADARx Pharmaceuticals has officially transitioned to the public markets, pricing an upsized initial public offering (IPO) that, when combined with a concurrent private placement from pharmaceutical giant AbbVie, has generated a massive capital infusion of $535.3 million. The company, which specializes in the development of small-interfering RNA (siRNA) therapies, priced its […]
The administrative burden of prescription drug costs has shifted significantly from the pharmacy counter to the clinical workspace, transforming the way modern medicine is practiced in the United States. While the debate over drug pricing is frequently centered on the financial strain experienced by patients, a newly released 2026 Physician Drug Cost Survey by RazorMetrics […]
Eli Lilly and Company has announced a significant expansion of its drug discovery pipeline through a new strategic research collaboration and license agreement with Beijing-based InnoCare Pharma. Under the terms of the agreement, the Indianapolis-based pharmaceutical giant will pay $100 million in upfront and near-term payments to leverage InnoCare’s proprietary technology platforms. This collaboration aims […]
The landscape of healthcare administration is undergoing a significant transformation as CertifyOS, a leader in provider data infrastructure, officially launched its National Shared Credentialing Program. This initiative, designed to dismantle the silos of provider verification, has secured immediate and formidable backing from three of the nation’s largest health insurance entities: UnitedHealthcare, Cigna Healthcare, and Centene. […]
The Series A round was led by .406 Ventures, a prominent healthcare-focused venture capital firm. Joining the round were several high-profile institutional investors, including Emerson Collective (managed by Yosemite), Forerunner Ventures, Serena Ventures—the investment firm founded by tennis icon Serena Williams—and Japan-based MPower Partners. The diverse backing underscores a growing confidence in the "Femtech" sector […]
The pharmaceutical landscape for rare kidney diseases witnessed a significant milestone this week as Roche announced positive interim results from its Phase 3 clinical trial of sefaxersen, an investigational treatment for immunoglobulin A nephropathy (IgAN). The data, derived from a prespecified interim analysis, demonstrated that sefaxersen achieved a statistically significant and clinically meaningful reduction in […]
